The widespread belief that cannabis effectively treats mental health conditions faces significant scientific scrutiny in light of accumulating research gaps and safety concerns. Despite millions of adults using cannabis for anxiety, depression, and PTSD management, the therapeutic foundation remains surprisingly weak, potentially exposing users to substantial risks without proven benefits.
This comprehensive JAMA review reveals that THC-dominant cannabis shows no clear improvement for PTSD symptoms and lacks sufficient evidence for treating anxiety, depression, or ADHD. Only cannabidiol (CBD) alone demonstrates emerging promise for anxiety disorders, though still with low-certainty evidence. Notably, about 30% of past-year cannabis users develop cannabis use disorder, with half experiencing moderate to severe impairment affecting employment and social functioning.
The risk profile proves particularly concerning for vulnerable populations. THC-predominant products can worsen mania symptoms in bipolar disorder and increase psychotic episodes in those with psychotic spectrum conditions. Regular high-THC use among adolescents carries additional developmental risks that the review emphasizes.
This analysis challenges the growing cultural narrative of cannabis as mental health medicine. While the endocannabinoid system clearly influences mood and anxiety pathways, translating this biological plausibility into clinical benefit has proven elusive. The disconnect between patient self-medication practices and scientific evidence suggests many may be substituting unproven cannabis products for established psychiatric treatments. For health-conscious adults, this review underscores the importance of evidence-based mental health approaches rather than relying on cannabis products with unclear efficacy and documented risks. The field desperately needs rigorous clinical trials to either validate or debunk cannabis mental health claims.